Jason Pinkstaff, Ph.D.
Vice President, Pharmacology and Toxicology
Dr. Pinkstaff joined AnaptysBio as Vice President, Pharmacology and Toxicology in August 2017 with over 20 years of research and development experience in the biotech and pharmaceutical industry. Prior to joining AnaptysBio, Dr. Pinkstaff headed the Pharmacology and Toxicology group at BioMarin Pharmaceutical Inc. and supported the nonclinical development of BioMarin’s late-stage research and clinical drug candidates as well as BioMarin’s commercial products in rare and orphan diseases. While at BioMarin, he played a significant role in the regulatory approval of Brineura for the treatment of Batten’s disease. Before joining BioMarin, Dr. Pinkstaff headed the Preclinical Sciences department at Ambrx, Inc. overseeing the nonclinical development of the internal pipeline across a wide range of therapeutic areas and modalities. While at Ambrx, he also providing oversight of partnered programs with BMS, Merck, Pfizer, Eli Lilly and Astellas through participation in joint steering committees including several clinical phase 2 assets the eventual approval of Imrestor with Eli Lilly. He has authored more than 30 patents and peer-reviewed manuscripts. Dr. Pinkstaff was a Postdoctoral Fellow at The Scripps Research Institute after receiving his Ph.D. in Neurobiology from University of California, Irvine and his B.S. in Biology from University of California, Los Angeles. He is a Diplomate of the American Board of Toxicology (DABT) and a Registered Toxicologist in Europe (ERT).